Manuscript
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242
Ernesto Maddaloni et al.
Diabetes Care 2025;48:e61-e62
Manuscript
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch DP et al.
Nat Commun. 2025;16:2124
Manuscript
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study
John M Dennis et al.
Lancet 2025;405:701-714
Manuscript
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL
Erenesto Maddaloni et al.
Diabetes Care 2025;48:235-242
Manuscript
The science of diabetes and a life of trials: The 2024 Banting Medal for Scientific Achievement Lecture
Rury R. Holman
Diabetes 2025;74:164-174
Manuscript
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply
Amanda I Adler et al.
Lancet 2025;405:29